API | difelikefalin

difelikefalin (Korsuva) Report issue

Small molecule Approved ^FDA Breakthrough Therapy ^FDA Priority Review ^FDA

AACT DrugBank PubChem

Active Ingredient History

NOW

Difelikefalin, sold under the brand name Korsuva, is an analgesic opioid peptide used for the treatment of moderate to severe itching. It acts as a peripherally specific, highly selective agonist of the κ-opioid receptor (KOR). ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanisms of Action:
- Kappa-type opioid receptor (Mus musculus) ^UniProt
- Kappa-type opioid receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

cr845 | difelikefalin

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (16)

Approved Indications (1)

Pruritus (approved 2021)

Experimental Indications - Clinical Trial Phases 1-4 (16)

Abdominal Pain (Phase 2/Phase 3)

Acute Pain (Phase 2)

Arthritis (Phase 2)

Dermatitis, Atopic (Phase 2)

Healthy Volunteers (Phase 1)

Joint Diseases (Phase 2)

Musculoskeletal Diseases (Phase 2)

Osteoarthritis (Phase 2)

Osteoarthritis, Hip (Phase 2)

Osteoarthritis, Knee (Phase 2)

Pain, Postoperative (Phase 2)

Paresthesia (Phase 2)

Pruritus (Phase 3)

Renal Dialysis (Phase 1)

Renal Insufficiency, Chronic (Phase 2)

Rheumatic Diseases (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 25
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue